;
Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Alere deal

    Alere Inc. (NYSE:ALR), Waltham, Mass. Business: Diagnostic Diagnostic company Alere said it received a letter from former President, CEO and Director Ron Zwanziger stating that he and former Alere directors David Scott …

    Published on 10/20/2014
  • Asterand Bioscience, ReproCell deal

    Asterand Bioscience Inc., Cambridge, Mass. ReproCell Inc. (JASDAQ:4978), Yokohama, Japan Business: Gene/Cell therapy ReproCell acquired the induced pluripotent stem cell (iPSC) reagents and services business of Stemgent…

    Published on 10/20/2014
  • BioCardia, CellProThera deal

    BioCardia Inc., San Carlos, Calif. CellProThera S.A.S., Mulhouse, France Business: Cardiovascular Early next year, CellProThera and BioCardia will conduct the Phase I/IIb EXCELLENT trial evaluating CellProThera's …

    Published on 10/20/2014
  • Bristol-Myers, J&J, Pharmacyclics deal

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif. Business: Cancer Bristol-Myers partnered with Pharmacyclics and …

    Published on 10/20/2014
  • Cancer Genetics, University of Southern California deal

    Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. University of Southern California, Los Angeles, Calif. Business: Diagnostic, Genomics Cancer Genetics partnered with a pathologist from Keck Medicine of the …

    Published on 10/20/2014
  • Cipla, Salix deal

    Cipla Ltd., Mumbai, India Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Business: Hepatic Cipla granted Salix exclusive, worldwide rights excluding Africa and Asia, but including Japan, to patent applications …

    Published on 10/20/2014
  • CoMentis, Astellas deal

    CoMentis Inc., South San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Neurology The companies ended a 2008 deal granting Astellas exclusive, worldwide rights to develop and commercialize …

    Published on 10/20/2014
  • ContraFect, China CDC deal

    ContraFect Corp. (NASDAQ:CFRX), Yonkers, N.Y. China Center for Disease Control and Prevention, Beijing, China Business: Infectious ContraFect and the center's National Institute for Viral Disease and Control (IVCD) …

    Published on 10/20/2014
  • Eisai, St. Jude Children's Research Hospital, Medicines for Malaria Venture deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan St. Jude Children's Research Hospital, Memphis, Tenn. Medicines for Malaria Venture, Geneva, Switzerland Business: Infectious Eisai partnered with St. Jude and Medicines for …

    Published on 10/20/2014
  • Immutep, Prima BioMed deal

    Immutep S.A., Orsay, France Prima BioMed Ltd. (ASX:PRR;NASDAQ:PBMD), Sydney, Australia Business: Autoimmune, Infectious, Cancer Prima will acquire cancer company Immutep for up to about $28 million in cash, shares and …

    Published on 10/20/2014
  • Isis Pharmaceuticals, GlaxoSmithKline deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Endocrine/Metabolic Isis received an $18 million milestone payment from GlaxoSmithKline under an …

    Published on 10/20/2014
  • Ligand, Merck deal

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious Ligand received a $550,000 milestone payment under a 2011 deal granting Merck a …

    Published on 10/20/2014
  • MabVax Therapeutics Holdings, Juno Therapeutics, Memorial Sloan Kettering deal

    MabVax Therapeutics Holdings Inc. (OTCQB:MBVX), San Diego, Calif. Juno Therapeutics Inc., Seattle, Wash. Memorial Sloan Kettering Cancer Center, New York, N.Y. Business: Cancer MabVax, Memorial Sloan Kettering Cancer …

    Published on 10/20/2014
  • Merck, Bayer deal

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cardiovascular, Pharmaceuticals Bayer completed its acquisition of Merck's consumer care business for $14.2 …

    Published on 10/20/2014
  • Orexigen, Takeda deal

    Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Endocrine/Metabolic Orexigen said it will receive a $70 million milestone payment from …

    Published on 10/20/2014
  • Oxford Real Estate Owner No. 2, Oxford BioMedica deal

    Oxford Real Estate Owner No. 2 Ltd., Oxford, U.K. Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Business: Biopharmaceuticals Oxford BioMedica purchased the Windrush Court laboratory and office space facility in Transport…

    Published on 10/20/2014
  • Paradigm, Forma Therapeutics deal

    Paradigm Inc., Ann Arbor, Mich. Forma Therapeutics Holdings LLC, Watertown, Mass. Business: Genomics Paradigm will identify genomic markers predictive of response for two of Forma's preclinical cancer compounds. Forma …

    Published on 10/20/2014
  • Pharmacyclics, Servier deal

    Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif. Servier, Neuilly-sur-Seine, France Business: Cancer The companies mutually terminated a 2009 deal granting Servier exclusive, ex-U.S. rights to develop and …

    Published on 10/20/2014
  • Regeneron, Columbia University, Clinic for Special Children, Baylor deal

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Columbia University, New York, N.Y. Clinic for Special Children, Strasburg, Pa. Baylor College of Medicine, Houston, Texas Business: Functional genomics …

    Published on 10/20/2014
  • Selecta, JDRF, Sanofi deal

    Selecta Biosciences Inc., Watertown, Mass. JDRF, New York, N.Y. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Endocrine/Metabolic Selecta and the not-for-profit JDRF added Sanofi as a new partner and extended …

    Published on 10/20/2014
  • Shire, Neos Therapeutics deal

    Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Neos Therapeutics Inc., Grand Prairie, Texas Business: Neurology Shire granted Neos a non-exclusive license to market Neos' amphetamine polistirex XR-ODT (NT-0202) for …

    Published on 10/20/2014
  • Sutro, University of California deal

    Sutro Biopharma Inc., South San Francisco, Calif. University of California, Calif. Business: Antibodies Sutro is providing its Xpress CF cell-free protein synthesis technology to a researcher at the University of …

    Published on 10/20/2014
  • Syntonix, Biovitrum deal

    Syntonix Pharmaceuticals Inc., Waltham, Mass. Biovitrum AB, Stockholm, Sweden Business: Hematology Swedish Orphan Biovitrum AB (SSE:SOBI, Stockholm, Sweden) exercised an option under a 2006 hemophilia deal with Biogen …

    Published on 10/20/2014
  • Targacept, AstraZeneca deal

    Targacept Inc. (NASDAQ:TRGT), Winston-Salem, N.C. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Neurology AstraZeneca ended an amended 2005 neurology deal with Targacept, which will regain all rights to …

    Published on 10/20/2014
  • University of Oxford, Sequenom deal

    University of Oxford, Oxford, U.K. Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Business: Diagnostic Sequenom purchased from the university's Isis Innovation Ltd. tech transfer arm IP covering noninvasive prenatal …

    Published on 10/20/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993